Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis

被引:117
作者
Scheper, Mark A. [1 ,2 ,3 ]
Badros, Ashraf [3 ]
Chaisuparat, Risa [2 ]
Cullen, Kevin J. [3 ]
Meiller, Timothy F. [2 ,3 ]
机构
[1] Univ Maryland, Med Ctr, Dept Diagnost Sci & Pathol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA
[3] Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD USA
关键词
zoledronic acid; apoptosis; fibroblasts; epithelium; bisphosphonate; CANCER-PATIENTS; PROTEIN PRENYLATION; RISK-FACTORS; JAW; OSTEOPOROSIS; PHARMACODYNAMICS; PHARMACOKINETICS; INHIBITION; THERAPY;
D O I
10.1111/j.1365-2141.2008.07504.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteonecrosis of the jaw secondary to bisphosphonate infusion (zoledronic acid-ZA) is assumed to be a bone disease. This study investigated the effects of ZA on soft tissues using oral mucosal cells as an in vitro model of soft tissue cell death in the pathogenesis of bone necrosis. Human gingival fibroblast and keratinocyte cell lines were exposed to different concentrations of ZA (0.25-3 mu mol/l), using 1 mu mol/l as the expected baseline concentration. A dose-response effect on apoptosis and cell proliferation [Terminal deoxynucleotidyl transferase-mediated dUTP-Biotin End Labelling and Annexin V or Coulter counter and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), respectively] was observed with increasing ZA concentrations; both reversed using siRNA against caspase 3 or 9. Gene expression analysis using RT(2) Profiler polymerase chain reaction Arrays demonstrated the differential expression of multiple genes involved in apoptosis including those that encode TNF, BCL-2, Caspase, IAP, TRAF and Death Domain families. Western blot analysis confirmed the presence of activated forms of caspase 3 and 9 and underexpression of survivin protein expression. This study demonstrated that low concentrations of ZA rapidly and directly affected the oral mucosal tissues though the induction of a gene-regulated apoptotic process. These findings support the potential for soft tissue injury as an initiating/potentiating event for osteonecrosis.
引用
收藏
页码:667 / 676
页数:10
相关论文
共 33 条
  • [1] Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors
    Badros, A
    Weikel, D
    Salama, A
    Goloubeva, O
    Schneider, A
    Rapoport, A
    Fenton, R
    Gahres, N
    Sausville, E
    Ord, R
    Meiller, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 945 - 952
  • [2] Jaw osteonecrosis associated with bisphosphonates:: Multiple exposed areas and its relationship to teeth extractions.: Study of 20 cases
    Bagan, JV
    Jimenez, Y
    Murillo, J
    Hernandez, S
    Poveda, R
    Sanchis, JM
    Díaz, JM
    Scully, C
    [J]. ORAL ONCOLOGY, 2006, 42 (03) : 327 - 329
  • [3] Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors
    Bamias, A
    Kastritis, E
    Bamia, C
    Moulopoulos, LA
    Melakopoulos, L
    Bozas, G
    Koutsoukou, V
    Gika, D
    Anagnostopoulos, A
    Papadimitriou, C
    Terpos, E
    Dimopoulos, MA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8580 - 8587
  • [4] Osteonecrosis of the jaw - Do biphosphonates pose a risk?
    Bilezikian, John P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) : 2278 - 2281
  • [5] Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
    Chen, TL
    Berenson, J
    Vescio, R
    Swift, R
    Gilchick, A
    Goodin, S
    LoRusso, P
    Ma, PM
    Ravera, C
    Deckert, F
    Schran, H
    Seaman, J
    Skerjanec, A
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11) : 1228 - 1236
  • [6] Use of intravenous bisphosphonates in osteoporosis
    Civitelli R.
    Napoli N.
    Armamento-Villareal R.
    [J]. Current Osteoporosis Reports, 2007, 5 (1) : 8 - 13
  • [7] Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation
    Coxon, JP
    Oades, GM
    Kirby, RS
    Colston, KW
    [J]. BJU INTERNATIONAL, 2004, 94 (01) : 164 - 170
  • [8] Pharmacokinetics/pharmacodynamics of bisphosphonates - Use for optimisation of intermittent therapy for osteoporosis
    Cremers, SCLM
    Pillai, GC
    Papapoulos, SE
    [J]. CLINICAL PHARMACOKINETICS, 2005, 44 (06) : 551 - 570
  • [9] Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases
    Dunford, JE
    Rogers, MJ
    Ebetino, FH
    Phipps, RJ
    Coxon, FP
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (05) : 684 - 694
  • [10] Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates
    Farrugia, MC
    Summerlin, DJ
    Krowiak, E
    Huntley, T
    Freeman, S
    Borrowdale, R
    Tomich, C
    [J]. LARYNGOSCOPE, 2006, 116 (01) : 115 - 120